Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Guselkumab Studied to Treat RA & Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  July 1, 2015

In a Phase 2 study, researchers evaluated the effectiveness of guselkumab to alleviate symptoms in patients with active RA suffering from tender and swollen joints.

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:EULARguselkumabMethotrexateplaque psoriasisRheumatoid arthritisustekinumab

Greece’s Medicine Supply May Be in Jeopardy

Ben Hirschler  |  June 29, 2015

BASEL, Switzerland (Reuters)—Drugmakers said on Monday they would continue to ship medicines to Greece in coming weeks, despite mounting unpaid bills, but warned supplies could be in jeopardy if Europe did not take emergency action. “In the worst-case scenario of ‘Grexit’, we believe the integrity of the medicines supply chain may be in jeopardy, which…

Filed under:Drug Updates Tagged with:Drug shortageEuropean UnionGreece

Lungs Are Particularly Vulnerable in Patients with Systemic Rheumatic Disease

Lara C. Pullen, PhD  |  June 29, 2015

In an observational study, physicians found that systemic rheumatic disease exacerbation and treatment-related infections were often related to the lungs…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:critical care managementInfectionlungrheumatologySystemic Rheumatic Diseases

U.S. Supreme Court Upholds Obamacare Insurance Subsidies

Lawrence Hurley  |  June 25, 2015

WASHINGTON (Reuters)—The U.S. Supreme Court preserved President Barack Obama’s signature healthcare law on Thursday, upholding crucial tax subsidies while turning aside a conservative legal challenge that could have doomed the law. “After more than 50 votes in Congress to repeal or weaken this law, after a presidential election based in part on preserving or repealing…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Health InsuranceLegislationObamacareSupreme Court

Antirheumatic Drugs May Be Linked to Pulmonary Toxicity & More

Michele B. Kaufman, PharmD, BCGP  |  June 24, 2015

At a recent symposium, Kristin Highland, MD, reported on the use of antirheumatic treatments, specifically methotrexate, and their connections with pulmonary toxicity in patients.

Filed under:Drug Updates Tagged with:ACR 2015 State-of-the-Art Clinical SymposiumDisease-modifying antirheumatic drugs (DMARDs)Methotrexatepulmonary toxicity

Many Psoriasis Patients Have Undiagnosed Arthritis

Kathryn Doyle  |  June 23, 2015

(Reuters Health)—Up to 15% of people with psoriasis have undiagnosed arthritis that’s related to the skin condition, according to a new review. “The important takeaway,” said Dr. Abby Van Voorhees, director of the Psoriasis and Phototherapy Treatment Center at the Hospital of the University of Pennsylvania in Philadelphia, “would be that further education is needed…

Filed under:ConditionsPsoriatic Arthritis Tagged with:DermatologyPsoriasisPsoriatic Arthritis

Screen Type 1 Diabetes & Pediatric Rheumatology Patients for Celiac Disease

Reuters Staff  |  June 20, 2015

NEW YORK (Reuters Health)—Screening for celiac disease (CD) is important in patients newly diagnosed with type 1 diabetes (T1D) and in children presenting for rheumatology evaluation, according to a pair of new reports. In a systematic review, online June 15 in Pediatrics, Australian researchers found most cases of CD are diagnosed within five years of…

Filed under:Conditions Tagged with:celiac diseasediabetespatient carePediatric Rheumatology

Public Rarely Knows Why FDA Rejects New Drugs

Lisa Rapaport  |  June 19, 2015

(Reuters Health)—Drug companies generally don’t disclose all the reasons new medicines fail to win U.S. marketing approval, even though regulators often reject treatments over concerns about safety or effectiveness, a study finds. Researchers compared the details companies made public in press releases with confidential documents from the U.S. Food and Drug Administration known as complete…

Filed under:Drug Updates Tagged with:drug developmentDrug SafetyFDA

Biosimilars for RA Studied in Multiple Trials

Michele B. Kaufman, PharmD, BCGP  |  June 17, 2015

Biosimilars for etanercept and sarilumab are being examined in multiple Phase 3 trials for their effects in RA and psoriasis patients.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic ArthritisRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsPsoriatic Arthritis

Zoledronic Acid May Improve Bone Density in Elderly Women

Anne Harding (Reuters Health)  |  June 15, 2015

A single injection daily of zoledronic acid may improve bone mineral density (BMD) in frail elderly women in long-term care facilities, a new randomized controlled trial shows. However, the clinical importance of the improvement, observed over a two-year period, remains unclear, Dr. Neil M. Resnick, of the University of Pittsburgh, told Reuters Health in a…

Filed under:Research Rheum Tagged with:bone densityoutcomeResearchWomenzoledronic acid

  • « Previous Page
  • 1
  • …
  • 242
  • 243
  • 244
  • 245
  • 246
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences